key: cord-0711959-atdbhh91 authors: Cerrud-Rodriguez, Roberto C.; Burkhoff, Daniel; Latib, Azeem; Granada, Juan F. title: A Glimpse Into the Future of Transcatheter Interventional Heart Failure Therapies date: 2021-11-24 journal: JACC Basic Transl Sci DOI: 10.1016/j.jacbts.2021.09.012 sha: 279540f798b8141546d580952d35e4d68d6f9df2 doc_id: 711959 cord_uid: atdbhh91 Chronic heart failure is one of the most debilitating chronic conditions affecting millions of people and adding a significant financial burden to health care systems worldwide. Despite the significant therapeutic advances achieved over the last decade, morbidity and mortality remain high. Multiple catheter-based interventional therapies targeting different physiological and anatomical targets are already under different stages of clinical investigation. The present paper provides a technical overview of the most relevant catheter-based interventional therapies under clinical investigation. H eart failure (HF) is a major global health problem carrying significant morbidity and mortality despite the introduction of novel pharmacological and device-based therapies (1) . Its prevalence has been estimated to increase to 2.97% of the U.S. population by 2030 (2) , whereas the total costs associated with HF care will more than double. It is estimated that by 2030, the cost of care will amount to $69.8 billion, up from $30. which propagates the remodeling process (6) . Specific to ischemic heart disease, necrotic myocardium undergoes fibrosis and scar formation (3) , which also contribute to LV remodeling (7) . Following this early stage, myocardial remodeling is predominantly driven by the hypertrophic myocyte elongation in the noninfarcted zone, as occurs in nonischemic dilated cardiomyopathy (8, 9) . Thus, changes in LV mass ultimately represent a maladaptive response and represent one the most frequently seen features in myocardial remodeling (5) , as this contributes to a worsened imbalance between energy supply and demand, as the degree of hypertrophy is generally unable to be compensated by capillary growth (10) . All these mechanical changes result in inefficient oxygen delivery from capillaries to myocytes (11) , resulting in subendocardial hypoperfusion and ischemia at times of high energy demand (10) . Surgical ventricular reconstruction aimed to reverse ventricular remodeling by excluding the infarcted akinetic region. However, in the overall study population, there were no changes in functional capacity, cardiac-related death, or rehospitalization rates (12) . Specifically, in the STICH (Surgical Treatment of Ischemic Heart Failure) trial (13) , 555 patients who underwent coronary artery bypass grafting plus surgical ventricular reconstruction and showed a postoperative LVESV index (LVESVi) #70 mL/m 2 by echocardiography experienced a survival benefit compared with coronary artery bypass grafting alone (13) . The benefit of this approach was less clear in patients with HF with reduced ejection fraction (HFrEF) and extensive ventricular dilation because it technically limits the ability to achieve sufficient reduction in LV volume (5) . In addition, the highly invasive nature and risk associated with this surgical procedure have led most major surgical centers to abandon this procedure (5) . The emergence of less invasive catheter- repeated as many times as needed at progressively more basilar levels so as to exclude as much of the infarcted, dyskinetic myocardium as possible. The first-generation system, used in 51 patients, required a median sternotomy. The current, secondgeneration system uses the less invasive LIVE procedure described previously and has been used in 35 higher speeds seem to increase the mean PA pressure, possibly owing to increased venous return (16, 22) . The system provides up to 5 L/min of flow at 30,000 rpm, with a mean flow of 3.5 L/min at 25,000 rpm. The device was tested in a single-center, is currently enrolling NYHA functional class III patients to assess the safety, performance, and usability of the V-LAP. Coincidentally, the first patient was enrolled immediately before the COVID-19 pandemic began, which allowed the researchers to remotely monitor his rising LAP using the implanted device, illustrating an impossible-to-foresee benefit of this technology (50) . We are eagerly awaiting for the results of this promising trial. jgranada@crf.org. Heart Disease and Stroke Statistics -2020 Update: a report from the Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment Impact of interatrial shunts on invasive hemodynamics and exercise tolerance in patients with heart failure Left ventricular volume reduction and reshaping as a treatment option for heart failure Left ventricular diastolic pressurevolume relations in rats with healed myocardial infarction. Effects on systolic function Favorable remodeling enhances recovery of regional myocardial function in the weeks after infarction in ischemically preconditioned hearts Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion Nonparallel changes in global left ventricular chamber volume and muscle mass during the first year after transmural myocardial infarction in humans Mechanisms of myocyte and capillary growth in the infarcted heart Left ventricular histomorphometric findings in dogs with heart failure treated with the Acorn cardiac support device Coronary bypass surgery with or without surgical ventricular reconstruction Insights from the STICH trial: change in left ventricular size after coronary artery bypass grafting with and without surgical ventricular reconstruction Less invasive ventricular reconstruction for ischaemic heart failure TCT-88 6-month outcomes of an early feasibility study of the AccuCinch Left Ventricular Repair system in patients with heart failure and functional mitral regurgitation Conceptual considerations for device-based therapy in acute decompensated heart failure: DRI(2) P(2)S. Circ Heart Fail Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment Cardiorenal interactions: insights from the ESCAPE trial The cardiorenal syndrome: do we need a change of strategy or a change of tactics? Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease Abdominal positioning of the next-generation intra-aortic fluid entrainment pump (Aortix) improves cardiac output in a swine model of heart failure A first-in-man study of the Reitan catheter pump for circulatory support in patients undergoing high-risk percutaneous coronary intervention Percutaneous haemodynamic and renal support in patients presenting with decompensated heart failure: A multi-centre efficacy study using the Reitan Catheter Pump (RCP) Cardiorenal syndrome: new perspectives Importance of venous congestion for worsening of renal function in advanced decompensated heart failure Intermittent occlusion of the superior vena cava reduces cardiac filling pressures in preclinical models of heart failure Treatment of diuretic resistance with a novel percutaneous blood flow regulator: concept and initial experience Reducing renal venous pressure with the Doraya Renal Flow Regulator -early FIM experience Regulation of stroke volume during submaximal and maximal upright exercise in normal man Effects of an interatrial shunt on rest and exercise hemodynamics: results of a computer simulation in heart failure Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction Guideline for the Management of Adults With Congenital Heart Disease: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Unidirectional left-to-right interatrial shunting for treatment of patients with heart failure with reduced ejection fraction: a safety and proof-ofprinciple cohort study Interatrial shunting for heart failure: early and late results from the first-in-human experience with the V-Wave system Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction The AFR-PRELIEVE trial: a prospective, nonrandomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction Stentless RF-based shunt solution -the NoYa system Percutaneous atriotomy for levoatrial-to-coronary sinus shunting in symptomatic heart failure: first-inhuman experience Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressureguided therapy for ambulatory heart failure Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first-inhuman study A rise in left atrial pressure detected by the V-LAPä system for patients with heart failure during the coronavirus disease 2019 pandemic KEY WORDS catheter-based therapies, heart failure